Search

Your search keyword '"Pierik, Marieke"' showing total 539 results

Search Constraints

Start Over You searched for: Author "Pierik, Marieke" Remove constraint Author: "Pierik, Marieke"
539 results on '"Pierik, Marieke"'

Search Results

2. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial

7. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission

8. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial

9. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility

10. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)

11. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study

13. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

14. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

15. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes.

16. Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply

17. Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission

19. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease

21. Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice : International Delphi Consensus Recommendations

22. Systematic review: Patient‐related, microbial, surgical, and histopathological risk factors for endoscopic post‐operative recurrence in patients with Crohn's disease.

24. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease

26. Vulvar and vaginal neoplasia in women with inflammatory bowel disease

31. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis

34. Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases

35. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

36. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases

37. Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations

38. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial

39. Early infliximab trough levels in paediatric IBD patients predict sustained remission.

41. Scoping review on health-related physical fitness in patients with inflammatory bowel disease:Assessment, interventions, and future directions

42. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes

43. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission:The Randomized Controlled LADI Trial

44. Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease:The POPEYE Randomized Controlled Clinical Trial

45. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry

47. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study

48. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)

50. The Intake of Dicarbonyls and Advanced Glycation Endproducts as Part of the Habitual Diet Is Not Associated with Intestinal Inflammation in Inflammatory Bowel Disease and Irritable Bowel Syndrome Patients

Catalog

Books, media, physical & digital resources